Pantarhei Bioscience B.v.

Donesta Bioscience B.v.

Monique Visser

Herman Jan Tijmen Coelingh Bennink

Herman Jan Coelingh Bennink

Herjan Jan Tijmen Coelingh Bennink

The present invention relates to the use of a steroid in the manufacture of a pharmaceutical composition for use in the therapeutic or prophylactic treatment of a hypertensive disorder of pregnancy (HDP) or fetal growth retardation, said treatment comprising administering to a female mammal a steroid selected from the group consisting of: substances represented by the following formula (formula I) in which formula R, R, R, Rindependently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; each of R, R, Ris a hydroxyl group; no more than 3 of R, R, R, Rare hydrogen atoms; precursors of such substances; and mixtures of one or more of the aforementioned substances and/or precursors. 

Treatment or prevention of hypertensive disorders of pregnancy or fetal growth retardation

One aspect of the present invention relates to the use of an estrogen in the treatment of Meconium Aspiration Syndrome (MAS) in a newborn infant, said treatment comprising administering an effective amount of estrogen to said newborn infant within 7 days after birth. The present treatment offers the advantage that estrogens can be administered using non-invasive modes of administration, e.g. oral or rectal administration. Other aspects of the present invention relate to a suppository for use in newborn infants comprising at least 1 &#x3bc;g of estrogen and to an oral applicator comprising a container holding an aqueous liquid containing micronised estetrol and a metering dispenser for metering the liquid into the oral cavity of a newborn infant.

Treatment of meconium aspiration syndrome with estrogens

The present invention relates to a method of preventing or treating benign estrogen sensitive gynecological disorders in a female mammal, wherein the method comprises the administration to said female mammal of a combination of progestogen and androgen in an amount that is therapeutically effective to prevent or reduce the symptoms of these disorders. The present method is particularly suitable for preventing or treating disorders selected from the group consisting of endrometriosis, adenomyosis, uterine fibroids, dysmenorrhoea, menorrhagia and metrorrhagia. Another aspect of the invention relates to a pharmaceutical kit comprising a plurality of oral dosage units which comprise a progestogen in an amount equivalent to 3-500 &#x3bc;g levonorgestrel and either 5 to 250 mg dehydroepiandrosterone or 1 to 50 mg testosterone undecanoate.

Method of preventing or treating benign gynaecological disorders

The invention relates to therapeutic and prophylactic treatment of ovarian cancer and metastases thereof. More specifically, the invention relates to immunogenic polypeptides comprising at least a portion of an ovarian tissue cell-associated protein or immunologically active variants thereof and to nucleic acids encoding such polypeptides and to the use thereof in immunotherapeutic methods of treatment. Said immunogenic polypeptides are provided by the zona pellucida (ZP) glycoproteins. ZP glycoproteins and fragments thereof that can induce a CD8and/or CD4T cell response as well as nucleic acid sequences encoding them can suitably be used in the present immunotherapeutic strategies.

Growing community of inventors

Zeist, Netherlands

Monique Visser